Gene BRCA1/2 mutation in prostate cancer patients: clinical administration aspects
| Autor: | P. V. Koposov |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2016 |
| Předmět: | |
| Zdroj: | Onkourologiâ, Vol 12, Iss 2, Pp 80-83 (2016) |
| ISSN: | 1996-1812 1726-9776 |
| Popis: | The cases of the uncommon malignant disease state can take place in patients with the prostate cancer. This disease may appear at a young age and the level of the PSA may be normal (to 4 ng / ml), and also the negative clinical prognosis, due to the resistance to standard medical treatment, can take place. In the literature review there is a data on patients’ carrier status of gene BRCA1 / 2 mutation. There are 2 % of such patients and the program of the target screening of the prostate cancer and the special treatment regimen for them should be developed. According to the mechanism of action of the platinum-based drugs and the data from the studies on treatment of the BRCA1 / 2-dependent ovarian cancer in women, where the high sensitivity to the platinum-based drugs in patients with the mutations of the reparation genes of the deoxyribonucleic acid by the homologous recombination was validated, we supposed, that the defects of the deoxyribonucleic acid reparation in patients with the metastatic castration-resistant prostate cancer also might be highly sensitive to the platinum-based drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|